These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 18266224)
21. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV. Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800 [TBL] [Abstract][Full Text] [Related]
22. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936 [TBL] [Abstract][Full Text] [Related]
23. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study. Glosli H; Bisogno G; Kelsey A; Chisholm JC; Gaze M; Kolb F; McHugh K; Shipley J; Gallego S; Merks JHM; Smeele LE; Mandeville H; Ferrari A; Minard-Colin V; Corradini N; Jenney M; Zanetti I; De Salvo GL; Orbach D; Eur J Cancer; 2021 Jul; 151():84-93. PubMed ID: 33971448 [TBL] [Abstract][Full Text] [Related]
24. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608 [TBL] [Abstract][Full Text] [Related]
25. Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in nonorbital parameningeal sites. A report from the Intergroup Rhabdomyosarcoma Study. Raney RB; Tefft M; Newton WA; Ragab AH; Lawrence W; Gehan EA; Maurer HM Cancer; 1987 Jan; 59(1):147-55. PubMed ID: 3791141 [TBL] [Abstract][Full Text] [Related]
26. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301 [TBL] [Abstract][Full Text] [Related]
27. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239 [TBL] [Abstract][Full Text] [Related]
28. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Pappo AS; Anderson JR; Crist WM; Wharam MD; Breitfeld PP; Hawkins D; Raney RB; Womer RB; Parham DM; Qualman SJ; Grier HE J Clin Oncol; 1999 Nov; 17(11):3487-93. PubMed ID: 10550146 [TBL] [Abstract][Full Text] [Related]
29. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Raney RB; Stoner JA; Walterhouse DO; Andrassy RJ; Donaldson SS; Laurie F; Meyer WH; Qualman SJ; Crist WM; Pediatr Blood Cancer; 2004 Jun; 42(7):618-25. PubMed ID: 15127417 [TBL] [Abstract][Full Text] [Related]
30. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Michalski JM; Meza J; Breneman JC; Wolden SL; Laurie F; Jodoin M; Raney B; Wharam MD; Donaldson SS Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1027-38. PubMed ID: 15234036 [TBL] [Abstract][Full Text] [Related]
31. Long-term results in children with head and neck rhabdomyosarcoma: A report from the Italian Soft Tissue Sarcoma Committee. Affinita MC; Ferrari A; Milano GM; Scarzello G; De Leonardis F; Coccoli L; Pericoli R; Basso E; Zanetti I; Scagnellato A; Bisogno G Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115716 [TBL] [Abstract][Full Text] [Related]
32. Parameningeal rhabdomyosarcoma: outcomes and opportunities. Yang JC; Wexler LH; Meyers PA; Wolden SL Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e61-6. PubMed ID: 23021437 [TBL] [Abstract][Full Text] [Related]
33. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group. Raney B; Huh W; Hawkins D; Hayes-Jordan A; Million L; Rodeberg D; Teot L; Anderson J; Pediatr Blood Cancer; 2013 Mar; 60(3):371-6. PubMed ID: 22961750 [TBL] [Abstract][Full Text] [Related]
35. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee. Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087 [TBL] [Abstract][Full Text] [Related]
37. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Koscielniak E; Klingebiel TH; Peters C; Hermann J; Burdach ST; Bender-Götze C; Müller-Weihrich ST; Treuner J Bone Marrow Transplant; 1997 Feb; 19(3):227-31. PubMed ID: 9028550 [TBL] [Abstract][Full Text] [Related]
38. Results of RS-99 protocol for childhood solid tumors. Cai JY; Tang JY; Pan C; Xu M; Xue HL; Zhou M; Dong L; Ye QD; Jiang H; Shen SH; Chen J World J Pediatr; 2010 Feb; 6(1):43-9. PubMed ID: 20143210 [TBL] [Abstract][Full Text] [Related]
39. Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India. Roy S; Pathy S; Mohanti BK; Chander S; Biswas A J Pediatr Hematol Oncol; 2017 Mar; 39(2):e62-e68. PubMed ID: 28060113 [TBL] [Abstract][Full Text] [Related]
40. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]